Company Snapshot
Celea Therapeutics is a Biotech company, based in Boston, Massachusetts, USA, founded 2025.
Recent changes
- Jul 2, 2026Jul 2, 2026Raised $180M Celea Therapeutics
- Jul 2, 2026Jul 2, 2026New investor: Leaps by Bayer Celea Therapeutics
- Jul 2, 2026Jul 2, 2026New investor: PureTech Health Celea Therapeutics
- Jul 2, 2026Jul 2, 2026New investor: RA Capital Celea Therapeutics
- Jul 2, 2026Jul 2, 2026Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug Pulse story
Earlier changes (1)
- Jul 2, 2026Jul 2, 2026Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3 Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 2, 2026 | funding round | $180M | — | Celea Therapeutics |
Investors
Latest Pulse
- Jul 6, 2026The Quiet IPO Pipeline Building Beneath the Mega-DealsA wave of new S-1 filings this week -- spanning cybersecurity, biotech, medical devices and SPAC vehicles -- shows a broader IPO pipeline building beneath the mega-cap headlines like Agility Robotics and SK Hynix.→
- Jul 5, 2026Biotech VCs Are Betting Big on Single Clinical TrialsCelea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.→
- Jul 4, 2026The Return of the $100M+ Vertical AI RoundTwelveLabs' $100M video-AI raise and Celea Therapeutics' $180M biotech round show growth-stage investors writing nine-figure checks into narrow, vertical AI applications again, not just horizontal infrastructure plays.→
- Jul 2, 2026Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.→
- Jul 2, 2026Scribe Therapeutics Files for $75M IPO to Test Early-Stage Biotech AppetiteScribe Therapeutics filed to raise up to $75 million in a Nasdaq IPO, becoming an early test of public-market appetite for Phase 1 biotechs -- its lead candidate, a CRISPR-based epigenetic therapy targeting PCSK9 to lower LDL cholesterol, is already in a.→
- Jul 2, 2026Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.→
Coverage Timeline
newest first- Jul 5, 2026FUNDINGBiotech VCs Are Betting Big on Single Clinical Trials$391M+ combined across 3 single-trial bets→
- Jul 4, 2026FUNDINGThe Return of the $100M+ Vertical AI Round$100M-$180M vertical AI rounds→
- Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug$180M Series B→
- Jul 2, 2026FUNDINGCelea Therapeutics Raises $180M to Push Lung Drug Into Phase 3$180 million→
All Coverage
FUNDING$391M+ combined across 3 single-trial bets
Biotech VCs Are Betting Big on Single Clinical Trials
Celea Therapeutics' $180M round, Beeline Medicine's $126.3M raise and Flare Therapeutics' $85M financing show late-stage biotech investors concentrating capital into single, high-conviction trial bets rather than diversified platform plays.
The Return of the $100M+ Vertical AI Round
FUNDING$100M-$180M vertical AI rounds
The Return of the $100M+ Vertical AI Round
TwelveLabs' $100M video-AI raise and Celea Therapeutics' $180M biotech round show growth-stage investors writing nine-figure checks into narrow, vertical AI applications again, not just horizontal infrastructure plays.
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
FUNDING$180M Series B
Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug
Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
FUNDING$180 million
Celea Therapeutics Raises $180M to Push Lung Drug Into Phase 3
PureTech-founded Celea Therapeutics raised $180 million to fund a head-to-head Phase 3 trial testing its drug deupirfenidone against the current standard of care for idiopathic pulmonary fibrosis.
Related Companies
Celea Therapeutics FAQ
Who are Celea Therapeutics's investors?
Celea Therapeutics's investors include RA Capital, Leaps by Bayer, PureTech Health (As of 2026-07-31T14:35:19Z).
Sources & methodologyshow
Where these figures come from
- Celea Therapeuticsprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.